Plasma Exchange

PreclinicalBiologic

Sanofi

Plasma Exchange is one of 128 biologic programs targeting Hepatitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Acute-on-Chronic Liver FailureActive, not recruiting

Chronic Liver FailureActive, not recruiting

Autoimmune HepatitisActive, not recruiting

PsychosisActive, not recruiting

Acute Liver FailureActive, not recruiting

Randomized Controlled TrialNot yet recruiting

MonotherapyUnknown status

HepatitisPreclinical

Active, not recruiting

Acute-on-Chronic Liver FailurePreclinical

Active, not recruiting

Chronic Liver FailurePreclinical

Active, not recruiting

Autoimmune HepatitisPreclinical

Active, not recruiting

PsychosisPreclinical

Active, not recruiting

Acute Liver FailurePreclinical

Active, not recruiting

Randomized Controlled TrialPreclinical

Not yet recruiting

MonotherapyPreclinical

Unknown status

Competition

Competitive Landscape

43 competitors in Hepatitis

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

2 2

Sovaldi

Gilead

Approved

1 3

Viread

Tyzeka

Glucophage

3 6

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 7

Singulair

OOrganon and Co

Approved

1 8

Epivir

GGlaxo Dba Glaxosmithkline

Approved

—9

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

8 10

Cellcept

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Acute Liver Failure

NCT06698991

Q1 2027

N/ANot yet recruiting

Autoimmune Hepatitis

NCT06855667

Q4 2027

N/ANot yet recruiting

Randomized Controlled Trial

NCT06276907

Clinical

Trials by Indication[1]

Acute Liver Failure2 trials

High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02718079·40 enrolled

Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06698991·20 enrolled

Randomized Controlled Trial1 trial

An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06276907·190 enrolled

Chronic Liver Failure1 trial

To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).

Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03162419

Psychosis1 trial

Study of Immunotherapy in Autoantibody Positive Psychosis

Completed·UUniversity of Cambridge·N/A·NCT02449746·10 enrolled

Hepatitis1 trial

Efficacy of Plasma Exchange Therapy vs Standard Medical Therapy in Severe Alcoholic Hepatitis With High Discriminant Function

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06355726·60 enrolled

5 more indications

Autoimmune Hepatitis1 trial

Efficacy and Safety of Therapeutic Plasma Exchange vs Standard Medical Therapy in Severe Autoimmune Hepatitis.

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06855667·50 enrolled

Monotherapy1 trial

Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04431375·70 enrolled

Acute-on-Chronic Liver Failure1 trial

Thromboelastography Guides a Multicentre Cluster Controlled Study of Plasma Exchange for Hepatitis B Associated Acute-on-chronic Liver Failure

Unknown status·NNanfang Hospital, Southern Medical University·N/A·NCT04747106·390 enrolled

COVID-191 trial

Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial

Terminated·FFundacion Clinic per a la Recerca Biomédica·Phase 2·NCT04374539·36 enrolled

Thrombotic Thrombocytopenic Purpura1 trial

A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Completed· Sanofi logo

Sanofi·Phase 2/3·NCT04074187·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Plasma Exchange. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plasma Exchange compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plasma Exchange. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Sanofi

Plasma Exchange

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Trials by Indication[1]

Acute Liver Failure2 trials

Randomized Controlled Trial1 trial

Chronic Liver Failure1 trial

Psychosis1 trial

Hepatitis1 trial

Autoimmune Hepatitis1 trial

Monotherapy1 trial

Acute-on-Chronic Liver Failure1 trial

COVID-191 trial

Thrombotic Thrombocytopenic Purpura1 trial

References

Drug Info

Quick Facts

Related News